TXMD Stock Forecast 2025-2026
Distance to TXMD Price Targets
TXMD Price Momentum
10 Quality Stocks Worth Considering Now
Researching TherapeuticsMD (TXMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TXMD and similar high-potential opportunities.
Latest TXMD Stock Price Targets & Analyst Predictions
TXMD has shown a year-to-date change of -15.1% and a 1-year change of -69.6%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for TXMD. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TXMD Analyst Ratings
TXMD Price Target Range
Latest TXMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TXMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 17, 2023 | Cantor Fitzgerald | Louise Chen | Neutral | Reiterates | $5.00 |
| Jan 11, 2023 | Cantor Fitzgerald | Louise Chen | Neutral | Reinstates | $5.00 |
| Jul 13, 2022 | Cantor Fitzgerald | Louise Chen | Neutral | Reiterates | $1.00 |
| Jun 7, 2022 | HC Wainwright & Co. | Neutral | Downgrade | $0.00 | |
| May 6, 2022 | Cantor Fitzgerald | Louise Chen | Neutral | Downgrade | $1.00 |
| Mar 11, 2022 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $2.50 |
| Nov 12, 2021 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $3.00 |
| Aug 7, 2020 | Jefferies | Chris Howerton | Underperform | Downgrade | $1.20 |
| May 19, 2020 | JP Morgan | Neutral | Downgrade | $0.00 | |
| May 7, 2020 | HC Wainwright & Co. | Buy | Reiterates | $5.00 | |
| May 7, 2020 | H.C. Wainwright | Buy | Reiterates | $0.00 | |
| Apr 16, 2020 | Stifel | Annabel Samimy | Buy | Maintains | $15.00 |
| Feb 21, 2020 | HC Wainwright & Co. | Buy | Maintains | $6.00 | |
| Feb 21, 2020 | H.C. Wainwright | Buy | Maintains | $0.00 | |
| Aug 14, 2018 | Cantor Fitzgerald | William Tanner | Overweight | Maintains | $27.00 |
| Jun 15, 2018 | JP Morgan | Overweight | Initiates | $0.00 | |
| Sep 8, 2017 | Morgan Stanley | Equal-Weight | Initiates | $0.00 | |
| Jul 21, 2017 | Deutsche Bank | Buy | Initiates | $0.00 | |
| Jul 11, 2017 | Oppenheimer | Outperform | Upgrade | $0.00 | |
| May 9, 2017 | Oppenheimer | Perform | Downgrade | $0.00 |
TherapeuticsMD Inc. (TXMD) Competitors
The following stocks are similar to TherapeuticsMD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TherapeuticsMD Inc. (TXMD) Financial Data
TherapeuticsMD Inc. has a market capitalization of $8.65M with a P/E ratio of 0.4x. The company generates $1.60M in trailing twelve-month revenue with a -207.8% profit margin.
Revenue growth is +133.8% quarter-over-quarter, while maintaining an operating margin of -157.0% and return on equity of -14.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
TherapeuticsMD Inc. (TXMD) Business Model
About TherapeuticsMD Inc.
Develops women's healthcare pharmaceutical products.
The company focuses on developing and commercializing hormone therapy solutions and prenatal vitamins aimed at addressing women's specific healthcare needs. By targeting menopause symptom management and providing essential nutrients, it creates revenue through the sales of these specialized products.
TherapeuticsMD Inc. emphasizes innovation in women's health and aims to fill gaps in pharmaceutical research, thus contributing to improved patient outcomes and expanding the options available in the women's healthcare market.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1
CEO
Country
United States
IPO Year
2007
Website
www.therapeuticsmd.comTherapeuticsMD Inc. (TXMD) Latest News & Analysis
TherapeuticsMD (NASDAQ: TXMD) reported a Q3 2024 net loss of $567K ($0.05 per share), an improvement from a $1.4M loss in Q3 2023.
TherapeuticsMD's reduced net loss signals potential improvement in financial health, which may influence investor sentiment and stock performance positively.
The Dow Jones index rose over 450 points on Friday, signaling positive market movement. Insider trading may reflect confidence or concerns about company prospects.
A 450-point gain in the Dow signals market optimism, while insider trading activity can reveal confidence or concerns about specific companies, influencing investment decisions.
TherapeuticsMD reported a net loss of $1.05 million for Q2 2024, improving from a $2.4 million loss in the same period last year. Loss per share was $(0.09).
TherapeuticsMD's reduced net loss signals improved financial performance, which may boost investor confidence and influence stock prices positively.
TherapeuticsMD (NASDAQ: TXMD) reported a Q1 2024 net loss of $0.8 million ($0.07 per share), an improvement from a loss of $2.3 million in the same quarter last year.
TherapeuticsMD reported reduced net loss in Q1 2024, signaling potential operational improvements. This may indicate a turnaround, affecting investor sentiment and stock valuation.
TherapeuticsMD (NASDAQ: TXMD) reported its 2023 financial results, with a focus on exploring strategic alternatives to enhance shareholder value, according to CEO Marlan D. Walker.
TherapeuticsMD's exploration of strategic alternatives signals potential changes that could enhance shareholder value, impacting stock performance and investor sentiment.
TherapeuticsMD (NASDAQ: TXMD) reported Q3 2023 results, emphasizing its transition to a royalty-based business and commitment to cost control to enhance royalty asset value.
TherapeuticsMD's shift to a royalty-based model and focus on cost control could enhance profitability, influencing stock performance and investor confidence in future earnings potential.
Frequently Asked Questions About TXMD Stock
What is TherapeuticsMD Inc.'s (TXMD) stock forecast for 2025?
Analyst forecasts for TherapeuticsMD Inc. (TXMD) are not currently available. The stock is trading at $0.73.
Is TXMD stock a good investment in 2025?
According to current analyst ratings, TXMD has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TXMD stock?
Price predictions from Wall Street analysts for TXMD are not currently available. The stock is trading at $0.73.
What is TherapeuticsMD Inc.'s business model?
The company focuses on developing and commercializing hormone therapy solutions and prenatal vitamins aimed at addressing women's specific healthcare needs. By targeting menopause symptom management and providing essential nutrients, it creates revenue through the sales of these specialized products.
What is the highest forecasted price for TXMD TherapeuticsMD Inc.?
Price targets from Wall Street analysts for TXMD are not currently available. The stock is trading at $0.73.
What is the lowest forecasted price for TXMD TherapeuticsMD Inc.?
Price targets from Wall Street analysts for TXMD are not currently available. The stock is trading at $0.73.
What is the overall TXMD consensus from analysts for TherapeuticsMD Inc.?
The overall analyst consensus for TXMD is bullish. Out of 6 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are TXMD stock price projections?
Stock price projections, including those for TherapeuticsMD Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
